Key Takeaway
A comprehensive Lancet meta-analysis confirms that higher daily step counts are associated with significantly lower risks of all-cause mortality, cardiovascular disease, cancer, and type 2 diabetes, with most benefits accruing by 8,000-10,000 steps per day.
Summary
Published in The Lancet Public Health in 2025, this large-scale systematic review and dose-response meta-analysis represents one of the most comprehensive assessments of the relationship between daily step counts and multiple health outcomes in adults. The study synthesized evidence from prospective cohort studies examining how daily steps relate to all-cause mortality, cardiovascular disease, cancer incidence, and type 2 diabetes risk.
The meta-analysis confirmed a consistent, nonlinear dose-response relationship across all outcomes examined. Higher daily step counts were significantly associated with reduced risks of all-cause mortality, cardiovascular disease, cancer, and type 2 diabetes. The most substantial risk reductions were observed when moving from low step counts to moderate levels (approximately 6,000-10,000 steps/day), with the curve flattening at higher step counts. The breadth of health outcomes examined beyond just mortality strengthens the case for daily walking as a multi-system health intervention.
This study is particularly significant because it goes beyond mortality to examine chronic disease outcomes, providing a more complete picture of the health benefits of walking. The Lancet publication and the scale of the analysis lend considerable weight to public health recommendations promoting daily step targets in the 8,000-10,000 range as optimal for broad health benefits.
Methods
Systematic review following PRISMA guidelines with searches across multiple databases for prospective cohort studies reporting on objectively measured daily step counts and health outcomes including all-cause mortality, cardiovascular disease, cancer, and type 2 diabetes. Dose-response relationships were modeled using nonlinear meta-analytic methods. Risk of bias assessed using established tools.
Key Results
- Significant inverse associations between daily steps and all-cause mortality, cardiovascular disease, cancer, and type 2 diabetes
- Nonlinear dose-response across all outcomes — steepest benefits between 4,000-10,000 steps/day
- Benefits for mortality, cardiovascular disease, and cancer plateaued around 8,000-10,000 steps/day
- Type 2 diabetes risk continued to decrease at higher step counts
- Consistent findings across subgroups stratified by age, sex, and geographic region
Limitations
- Observational evidence only; cannot confirm causal relationships
- Variability in accelerometer/pedometer devices and wear-time criteria across studies
- Potential reverse causation (unhealthy individuals may walk less at baseline)
- Single baseline measurement of step count may not capture changes over time
- Publication bias possible given positive findings across nearly all studies